Deloitte China assists the listing of Jiangxi Bio on SEHK
Deloitte China supported the listing of Jiangxi Institute of Biological Products Inc. (“Jiangxi Bio”, stock code: 06915.HK) on the Stock Exchange of Hong Kong (SEHK) on 30 June 2026.
In this global offering, Jiangxi Bio offered 36.2 million shares at HKD11.20 each, raising approximately HKD405.6 million.
David Yu, Audit & Assurance (A&A) Growth officer (3rd from the left); Jing Yue, Jiangxi Bio’s chairman of the Board (6th from the left) and representatives of other professional intermediaries attend the listing ceremony of Jiangxi Bio at Hong Kong Stock Exchange.
(from left) Beata Li, senior, Deloitte China A&A; Felix Dong, A&A manager; Kathy Xu, A&A manager; Carie Yao, A&A senior manager; Jacqueline Chow, Southern Region Offering Services partner of Capital Market Services Group (7th from the left); David Yu (8th from the left); Jing Yue, Jiangxi Bio’s chairman of the Board (9th from the left); Yao Xiaodong, Jiangxi Bio’s executive director (10th from the left) and representatives of other professional intermediaries attend the listing ceremony of Jiangxi Bio at Hong Kong Stock Exchange.
(from left) Iris Yao, Associate, Deloitte China A&A; Beata Li, Felix Dong, Carie Yao, Jing Yue, Jacqueline Chow, Kathy Xu, and Amber Huang, A&A associate attend the listing ceremony of Jiangxi Bio at Hong Kong Stock Exchange.
Client overview
Jiangxi Bio is a provider and exporter of human tetanus antitoxins (‘‘Human TAT’’).
According to Frost & Sullivan, in the financial year of 2025, Jiangxi Bio was the largest Human TAT provider in China and globally in terms of sales volume in 2025. Jiangxi Bio was also the largest Human TAT provider in China and globally in terms of revenue.
Jiangxi Bio has been consistently dominated the Human TAT market in China, maintaining a market share of above 50% for 19 consecutive years.
Deloitte's role
The listing of Jiangxi Bio spanned industry cycles, bearing witness to the resilience of the company and Deloitte's service teams. As a core service institution of this new listing engagement, Deloitte China was deeply involved in the entire process of the IPO. This successful listing demonstrates Deloitte’s rich professional expertise and capital market service capabilities. The engagement team worked closely with various professional parties and provided high-quality services with rich industry experience and excellent professional capabilities to assist Jiangxi Bio in listing on the Main Board of the SEHK.
Deloitte China congratulates Jiangxi Bio on its successful listing on the SEHK. We will continue to provide high-quality professional services and outstanding resource integration to assist more clients in staying one-step ahead in today's increasingly competitive and complex business environment.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see About Deloitte to learn more.
Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China’s reform, opening-up and economic development. We are a globally connected firm with deep roots locally, owned by our partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.
We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.
The Deloitte brand originated in 1845, and its name in Chinese (德勤) denotes integrity, diligence and excellence. Deloitte's global professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, empower talents to be future-ready, and lead the way toward a stronger economy, a more equitable society and a sustainable world.
This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms or their related entities (collectively, the “Deloitte organization”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.
No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.
